Alamar Biosciences, Inc. (ALMR)
| Market Cap | 1.49B |
| Revenue (ttm) | 87.16M +195.2% |
| Net Income | -43.49M |
| EPS | -3.69 |
| Shares Out | 69.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 133,325 |
| Open | 20.95 |
| Previous Close | 20.94 |
| Day's Range | 20.95 - 22.10 |
| 52-Week Range | 18.85 - 27.20 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 30.00 (+39.6%) |
| Earnings Date | May 8, 2026 |
About ALMR
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnosti... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ALMR stock is "Buy." The 12-month stock price target is $30.0, which is an increase of 39.60% from the latest price.
News
Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices | Workflow extends NULISA into longitudin...
Alamar Biosciences Slides: FY 2026
Alamar Biosciences has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 12, 2026.
Alamar Biosciences initiated with an Outperform at Leerink
Leerink initiated coverage of Alamar Biosciences (ALMR) with an Outperform rating and $35 price target Core to the firm’s thesis is the differentiated, highly automated ARGO HT instrument, NULISA tech...
Alamar Biosciences initiated with a Neutral at BofA
BofA initiated coverage of Alamar Biosciences (ALMR) with a Neutral rating and $27 price target The emerging growth life science tools company with a cutting edge platform for the study…
Alamar Biosciences initiated with a Buy at TD Cowen
TD Cowen analyst Dan Brennan initiated coverage of Alamar Biosciences (ALMR) with a Buy rating and $30 price target The company’s Nulisa chemistry and “easy-to-use, robust” Argo platform offer a…
Alamar Biosciences initiated with an Overweight at JPMorgan
JPMorgan analyst Casey Woodring initiated coverage of Alamar Biosciences (ALMR) with an Overweight rating and $30 price target Alamar is a proteomics platform company with a nucleic acid linked immuno...
Alamar Biosciences initiated with a Buy at Stifel
Stifel initiated coverage of Alamar Biosciences (ALMR) with a Buy rating and $28 price target Alamar is an emerging multiplex proteomics player that has seen rapid adoption of its ARGO…
Alamar Biosciences reports Q1 EPS ($1.74) vs. (68c) last year
Reports Q1 revenue $26.04M vs. $13.09M last year. “We began 2026 with a record quarter, nearly doubling revenue year over year as our NULISA platform gained rapid global traction among…
Alamar Biosciences Earnings release: Q1 2026
Alamar Biosciences released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Alamar Biosciences Quarterly report: Q1 2026
Alamar Biosciences has published its Q1 2026 quarterly earnings report on May 8, 2026.
Alamar Biosciences Reports First Quarter 2026 Financial Results
FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported fina...
Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference
FREMONT, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it ...
Alamar Biosciences to Report First Quarter 2026 Financial Results on May 8, 2026
FREMONT, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced i...
Alamar Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
FREMONT, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (“Alamar”), a leader in Precision Proteomics dedicated to advancing the early detection of disease, today announced the clo...
Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ
SHANGHAI, April 20, 2026 /PRNewswire/ -- Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ Stock Exchang...
Cathie Wood’s ARK Investment buys 537.5K shares of Alamar Biosciences today
20:08 EDT Cathie Wood’s ARK Investment buys 537.5K shares of Alamar Biosciences (ALMR) today
Alamar Biosciences valued at $1.5 billion as shares jump in Nasdaq debut
Shares of Alamar Biosciences jumped 33% in their Nasdaq debut on Friday, valuing the protein biomarker detection platform at $1.53 billion.
Alamar Biosciences opens at $22.60, IPO priced at $17 per share
Alamar Biosciences (ALMR) priced 11.25M shares at $17.00. The deal size was increased and priced at the high-end of the range. Alamar is a life sciences company that says its…
Alamar Biosciences indicated to open at $20, IPO priced at $17
Alamar Biosciences (ALMR) priced 11.25M shares at $17.00. The deal size was increased to 11.25M shares of common stock from 9.375M shares and priced at the high-end of the $15.00-$17.00…
Alamar Biosciences 11.25M share IPO priced at $17.00
The deal size was increased to 11.25M shares of common stock from 9.375M shares of common stock and priced at the high-end of the $15.00-$17.00 range. JPMorgan, BofA, TD Cowen,…
Alamar Biosciences Announces Pricing of Upsized Initial Public Offering
Alamar Biosciences, Inc., a leader in precision proteomics dedicated to advancing the early detection of disease...
Alamar Biosciences Registration statement: Registration filing
Alamar Biosciences filed a registration statement on April 16, 2026, providing details about a securities offering with the SEC.
Alamar Biosciences Registration statement: Registration filing
Alamar Biosciences filed a registration statement on April 13, 2026, providing details about a securities offering with the SEC.
Protein biomarker detection platform Alamar Biosciences files for a $100 million IPO
Alamar Biosciences, which provides a protein biomarker detection platform for disease detection research, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Alamar Biosciences IPO Registration Document (S-1)
Alamar Biosciences has filed to go public with an IPO on the NASDAQ